Investigation announced for Investors in shares of Ascendis Pharma A/S (NASDAQ: ASND) over potential Wrongdoing

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Ascendis Pharma A/S.

Investors who purchased shares of Ascendis Pharma A/S (NASDAQ: ASND) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Ascendis Pharma A/S directors breached their fiduciary duties and caused damage to the company and its shareholders.

Denmark based Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. Ascendis Pharma A/S reported that its annual Total Revenue rose from 7.77 million EUR in 2021 to 51.17 million EUR in 2022, and that its Net Loss increased from 383.57 million EUR in 2021 to 583.19 million EUR in 2022.

On April 3, 2023, before market hours, Ascendis Pharma A/S announced that the "U.S. Food & Drug Administration ("FDA") has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company's New Drug Application ("NDA") for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter."

Shares of Ascendis Pharma A/S (NASDAQ: ASND) declined from $134.52 per share in November 11, 2022, to as low as $64.33 per share on April 3, 2023.

Those who purchased shares of Ascendis Pharma A/S (NASDAQ: ASND) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.